Navigation Links
New Analysis from Roswell Park Epidemiologists Shows Unexpected Benefit Related to High Blood Pressure for Many with Ovarian Cancer
Date:4/13/2017

Hypertension, or high blood pressure, may come with a plus side, at least for a subset of women with ovarian cancer. New research from epidemiologists at Roswell Park Cancer Institute, published in the journal Cancer Causes & Control, provides evidence that hypertension and diabetes and the use of medications to treat these common conditions may influence the survival of ovarian cancer patients — sometimes in a detrimental way, but in the case of hypertension medications, perhaps as a benefit.

Using pooled data from 15 studies that were part of the Ovarian Cancer Association Consortium, an international team of collaborators led by Kirsten Moysich, PhD, MS, and Albina Minlikeeva, PhD, MPH, retroactively examined the associations between survival among patients diagnosed with invasive epithelial ovarian cancer and those patients’ history of hypertension, heart disease, diabetes, and medications taken for those conditions.

They found that while a history of diabetes was associated with a 112% higher risk of mortality across more than 7,600 cases, no significant mortality associations were observed for hypertension or heart disease. In fact, the authors report, among women with endometrioid ovarian cancer, a subtype of epithelial ovarian cancer typically associated with better outcomes, hypertension — a condition that applied to nearly 26% of women in the pooled analysis — was associated with 46% lower risk of ovarian cancer progression.

“This is a coincidental and unintended consequence of hypertension and its treatment, but it’s a silver lining to a serious but largely manageable medical condition that has reached epidemic prevalence in the U.S. and many other countries worldwide,” says Dr. Moysich, Distinguished Professor of Oncology in the departments of Cancer Prevention and Control and Immunology at the Buffalo cancer center.

This study is the first to highlight the role of comorbidities in relation to ovarian cancer survival by histological subtype, and confirmed previous findings linking a history of diabetes to increased risk of death among ovarian cancer patients. It’s possible that commonly prescribed antihypertensive medications, including beta blockers, may influence the growth of ovarian tumors. But the team also documented a higher overall risk of death for patients who had ever taken beta blockers, and notes that further study is needed to better understand these processes and interactions.

“Our results suggest that it is important to investigate factors that explain the difference in cancer outcomes among women with different types of ovarian cancer. Most studies only consider clinical characteristics at diagnosis, such as stage and histology in relation to ovarian cancer prognosis,” adds Dr. Minlikeeva, a postdoctoral Research Affiliate with Roswell Park’s Department of Cancer Prevention and Control. “Our findings emphasize the importance of understanding the full clinical profile for women with ovarian cancer in order to predict ovarian cancer outcomes.”

Approximately 22,300 new cases of ovarian cancer are diagnosed each year in the U.S., with an estimated 14,200 women dying from the disease each year. Endometrioid carcinoma accounts for about 20% of all epithelial ovarian cancers.

The study, “History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium,” is available at link.springer.com. This work was funded in part by grants and contracts from the National Cancer Institute (project nos. K07CA080668, K07CA095666, K22CA138563, N01CN55424 P30CA072720, P50CA105009, P50CA159981, R01CA074850, R01CA080742, R01CA095023, R01CA112523, R01CA126841, R01CA188900, R01CA54419, R01CA58598, R01CA61107, R01CA76016, R01CA87538, R25CA113951 and T32CA108456), National Library of Medicine (project no. K01LM012100), Division of Cancer Control and Population Sciences (project no. N01PC67001) and Roswell Park Alliance Foundation. A full list of funders is available in the Acknowledgments section at that link.

For an online version of this release, please visit: https://www.roswellpark.org/media/news/epidemiological-analysis-shows-unexpected-benefit-related-high-blood-pressure-many

###

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci(at)roswellpark(dot)org. Follow Roswell Park on Facebook and Twitter.

Read the full story at http://www.prweb.com/releases/2017/04/prweb14243885.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Medical Tourism Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
2. MediPoint: Total Hip Replacement - APAC Analysis and Market Forecasts
3. MediPoint: Total Hip Replacement - South American Analysis and Market Forecasts
4. Medical Disposables Market (Drug Delivery, Wound Management Products, Non-Woven Medical Disposables) – Global & US Industry Analysis and Trends To 2018
5. Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, etc.) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
6. Global Multiparameter Patient Monitoring Equipment Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012-2016
7. China Osteoporosis Drug Market 2013 Analysis & 2017 Forecasts in New Research Report at ChinaMarketResearchReports.com
8. Analysis of health care in US indicates that improvement in outcomes has slowed
9. PTT Telemedicine Market and M-Health Convergence Analysis in 2013-2019 Report Now Available with ReportsnReports.com
10. Global Pain Management Devices Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
11. India In Vitro Diagnostics (IVD) Market Analysis and 2018 Forecasts in New Research Report at MarketReportsOnline.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... 22, 2017 , ... Faithfully following pop culture, people today are forever in ... shaped through fitness programs. It carries on to skin nourished, pampered and nurtured to ... radiant smile. CDA has found that just like a perfectly cut and ...
(Date:5/22/2017)... ... 2017 , ... OSF Ventures, the corporate investment arm of ... stage company in San Francisco that has developed software to individualize treatment based ... acted as the lead investor in the round. , Medicine is typically ...
(Date:5/21/2017)... ... May 19, 2017 , ... HealthSmart, the ... of James (Jim) Vertino as Chief Information Officer (CIO). He will be joining ... drives innovation and business performance. He defines strategic roadmaps by reimagining business processes—bridging ...
(Date:5/21/2017)... Viejo, CA (PRWEB) , ... May 20, 2017 ... ... self-animating, paragraph styled corporate text designs created specifically for use in Final Cut ... editing process for all media productions. Pixel Film Studios’ ProParagraph Corporate will deliver ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... brought together a cross-disciplinary group of scholars, policymakers, and activists wanting to address ... and Equity is the third book from a recent series of from ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" ... to be the first to eliminate the need for embryonic ... cells to treat neurodegenerative diseases. Fortuna ... with Professor Michael Fehlings , MD, PhD; Father ... , MD, MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)...  A new tight-tolerance microextrusion medical tubing product ... is being launched by Natvar, a Tekni-Plex company. ... recent years to service a wide variety of ... expensive materials such as glass and fluoropolymers have ... their ability to consistently hold tolerances. This is ...
(Date:5/3/2017)... , May 3, 2017  West Pharmaceutical Services, ... solutions for injectable drug administration, announced today that ... and Technical Services, and Diane Paskiet , ... offering presentations focused on West,s expertise in the ... as well as providing commentary on updated industry ...
Breaking Medicine Technology: